Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
David G. Poplack(Baylor College of Medicine), David G. Johns(Marine Biological Association of the United Kingdom), Richard S. Ungerleider(Unknown), Jeffrey M. Lipton(Northwell Health), Stephen E. Sallan, Peter Venner(Cancer Institute (WIA)), John S. Holcenberg(Children's of Alabama), Daniel Glaubiger(National Institutes of Health), Gaston K. Rivera(St. Jude Children's Research Hospital), Sharon B. Murphy(University of New Hampshire), Julie Blatt(Center for Cancer and Blood Disorders)
PubMed
September 1, 1981
Cited by 87
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
|Journal of Clinical Oncology|1996|1.6k
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|1999|1.2k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914